Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

Recent Analyst Ratings for
$PBM

$PBM
Large Ownership Changes

Chat with this insight

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Psyence Biomedical Ltd.

Introducing Nullity AI - Build Your AI Search Engine in 30 Seconds

12/4/24 4:38:27 PM ET

$PBM

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PBM alert in real time by email

SC 13G/A 1 d900537dsc13ga.htm SC 13G/A SC 13G/A

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Psyence Biomedical Ltd.

(Name of Issuer)

Class A Common Stock, par value $0.0001 per share

(Title of Class of Securities)

74449F209

(CUSIP Number)

(formerly 74449F100)

December 2, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Continued on following pages

Page 1 of 11 Pages

Exhibit Index: 10 Page


CUSIP No. 74449F209				Page 2 of 11 Pages


CUSIP No. 74449F209				Page 3 of 11 Pages


CUSIP No. 74449F209				Page 4 of 11 Pages


CUSIP No. 74449F209				Page 5 of 11 Pages


CUSIP No. 74449F209				Page 6 of 11 Pages


CUSIP No. 74449F209				Page 7 of 11 Pages


CUSIP No. 74449F209				Page 8 of 11 Pages

Item 1(a).

Name of Issuer

Psyence Biomedical Ltd. (the “issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices

121 Richmond Street West, Penthouse Suite 1300, Toronto, Ontario M5H 2K1, Canada

Item 2(a).

Names of Persons Filing

This Statement is filed on behalf of the following persons (collectively, the “Reporting Persons”):

Harraden Circle Investors, LP (“Harraden Fund”),

ii)

Harraden Circle Special Opportunities, LP (“Harraden Special Op Fund”)

iii)

Harraden Circle Investors GP, LP (“Harraden GP”);

iv)

Harraden Circle Investors GP, LLC (“Harraden LLC”);

Harraden Circle Investments, LLC (“Harraden Adviser”); and vi) Frederick V. Fortmiller, Jr. (“Mr. Fortmiller”);

This Statement relates to Shares (as defined herein) directly beneficially owned by Harraden Fund and Harraden Special Op Fund. Harraden GP is the general partner to Harraden Fund and Harraden Special Op Fund, and Harraden LLC is the general partner of Harraden GP. Harraden Adviser serves as investment manager to Harraden Fund, Harraden Special Op Fund and other high net worth individuals. Mr. Fortmiller is the managing member of each of Harraden LLC and Harraden Adviser. In such capacities, each of Harraden GP, Harraden LLC, Harraden Adviser and Mr. Fortmiller may be deemed to indirectly beneficially own the Shares reported herein directly beneficially owned by Harraden Fund and Harraden Special Op Fund.

Item 2(b).

Address of Principal Business Office or, if None, Residence

The address of the principal business office of each Reporting Person is 299 Park Avenue, 21st Floor, New York, NY 10171.

Item 2(c).

Citizenship

Each of Harraden Fund, Harraden Special Op Fund and Harraden GP is a Delaware limited partnership. Each of Harraden LLC and Harraden Adviser is a Delaware limited liability company. Mr. Fortmiller is a citizen of the United States of America.

Item 2(d).

Title of Class of Securities

Class A Common Stock, par value $0.0001 per share (“Shares”)

Item 2(e).

CUSIP No. 74449F209

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: This Item 3 is not applicable.


CUSIP No. 74449F209				Page 9 of 11 Pages

Item 4.

Ownership

Item 4(a)

Amount Beneficially Owned

As of December 2, 2024, each of the Reporting Persons may be deemed the beneficial owner of 151,010 Shares held directly by Harraden Fund, Harraden Special Op Fund and Harraden Adviser.

Item 4(b)

Percent of Class Fund and Harraden Adviser.

As of December 2, 2024, each of the Reporting Persons may be deemed the beneficial owner of approximately 15.16% of Shares outstanding. This percentage is based on a total of 996,070 Shares outstanding, based on information in the Form F-1 filed by the Company on October 30, 2024, adjusted for a reverse split effective on November 26, 2024.

Item 4(c)

Number of shares as to which such person has:


(i) Sole power to vote or direct the vote:			0
(ii) Shared power to vote or direct the vote:			151,010
(iii) Sole power to dispose or direct the disposition of:			0
(iv) Shared power to dispose or direct the disposition of:			151,010

Item 5.

Ownership of Five Percent or Less of a Class

This Item 5 is not applicable.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

This Item 6 is not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

See disclosure in Item 2 hereof.

Item 8.

Identification and Classification of Members of the Group

This Item 8 is not applicable.

Item 9.

Notice of Dissolution of Group

This Item 9 is not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


CUSIP No. 74449F209				Page 10 of 11 Pages

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: December 4, 2024


HARRADEN CIRCLE INVESTORS, LP

HARRADEN CIRCLE SPECIAL OPPORTUNITIES, LP

By:		HARRADEN CIRCLE INVESTORS GP, LP, its general partner

By:		HARRADEN CIRCLE INVESTORS GP, LLC, its general partner

By:		/s/ Frederick V. Fortmiller, Jr.
Title:		Managing Member

HARRADEN CIRCLE INVESTORS GP, LP

By:		HARRADEN CIRCLE INVESTORS GP, LLC, its general partner

By:		/s/ Frederick V. Fortmiller, Jr.
Title:		Managing Member

HARRADEN CIRCLE INVESTORS GP, LLC

By:		/s/ Frederick V. Fortmiller, Jr.
		Managing Member

HARRADEN CIRCLE INVESTMENTS, LLC

By:		/s/ Frederick V. Fortmiller, Jr.
		Managing Member

FREDERICK V. FORTMILLER, JR.

/s/ Frederick V. Fortmiller, Jr.


CUSIP No. 74449F209				Page 11 of 11 Pages

Exhibit INDEX


Joint Filing Agreement		11

Get the next $PBM alert in real time by email

NAMES OF REPORTING PERSONS

Harraden Circle Investments, LLC

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐ (b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware